

Young Joon Byun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6916926/publications.pdf>

Version: 2024-02-01

18
papers

217
citations

933447

10
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

308
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. <i>Prostate International</i> , 2022, 10, 1-6.	2.3	5
2	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. <i>Investigative and Clinical Urology</i> , 2022, 63, 238.	2.0	3
3	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	2
4	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 237.e21-237.e29.	1.6	12
5	Collagen type $\alpha 1$ and 2 repress the proliferation, migration and invasion of bladder cancer cells. <i>International Journal of Oncology</i> , 2021, 59, .	3.3	21
6	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 340.	2.0	14
7	Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12756.	4.1	7
8	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. <i>Oncology Letters</i> , 2020, 19, 476-486.	1.8	9
9	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. <i>Investigative and Clinical Urology</i> , 2020, 61, 411.	2.0	7
10	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e704-e711.	1.9	12
11	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array-based DNA methylation profiling. <i>Oncology Reports</i> , 2019, 42, 453-460.	2.6	6
12	Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria. <i>International Journal of Cancer</i> , 2019, 144, 380-388.	5.1	30
13	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 86-96.	1.6	11
14	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. <i>Journal of Korean Medical Science</i> , 2019, 34, e144.	2.5	17
15	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 274-280.	1.9	8
16	<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. <i>Journal of Korean Medical Science</i> , 2018, 33, e303.	2.5	19
17	Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer. <i>Oncotarget</i> , 2018, 9, 27656-27666.	1.8	20
18	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 450-454.	1.9	14